Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03316300
Recruitment Status : Recruiting
First Posted : October 20, 2017
Last Update Posted : December 11, 2019
Sponsor:
Information provided by (Responsible Party):
Neurotech Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : March 31, 2022